GILD9:41 PMCORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Resultsgilead.com
GILD6:26 AMCHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancergilead.com
GILD4:05 PMGilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026gilead.com
GILD10:00 AMGilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Curegilead.com
GILD10:00 AMInvestigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapygilead.com